Research programme: adenosine receptor antagonists - Corvus/Vernalis
Alternative Names: Adenosine A2B receptor antagonist - Corvus/Vernalis; Immune checkpoint inhibitor B - Corvus/Vernalis; VER 4066; VER 4187; VER 6623; VER 6947; VER 7835Latest Information Update: 09 Apr 2021
At a glance
- Originator Vernalis
- Developer Corvus Pharmaceuticals; Vernalis
- Class Purines; Pyrimidines; Thiophenes
- Mechanism of Action Adenosine A2 receptor antagonists; Adenosine A2B receptor antagonists; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
- Discontinued Anxiety disorders; Major depressive disorder
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for research development in Cancer in USA
- 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
- 04 Jan 2016 Early research in Cancer in USA (unspecified route)